4894 Stock Overview
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cuorips Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,325.00 |
| 52 Week High | JP¥4,075.00 |
| 52 Week Low | JP¥1,287.00 |
| Beta | 0 |
| 1 Month Change | -10.01% |
| 3 Month Change | 34.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 153.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4894 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -2.8% | 4.5% | 2.1% |
| 1Y | n/a | -24.4% | 27.5% |
Return vs Industry: Insufficient data to determine how 4894 performed against the JP Biotechs industry.
Return vs Market: Insufficient data to determine how 4894 performed against the JP Market.
Price Volatility
| 4894 volatility | |
|---|---|
| 4894 Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4894's share price has been volatile over the past 3 months.
Volatility Over Time: 4894's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Takayuki Kusanagi | cuorips.co.jp |
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services.
Cuorips Inc. Fundamentals Summary
| 4894 fundamental statistics | |
|---|---|
| Market cap | JP¥26.21b |
| Earnings (TTM) | -JP¥598.00m |
| Revenue (TTM) | JP¥40.00m |
655.2x
P/S Ratio-43.8x
P/E RatioIs 4894 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4894 income statement (TTM) | |
|---|---|
| Revenue | JP¥40.00m |
| Cost of Revenue | JP¥21.00m |
| Gross Profit | JP¥19.00m |
| Other Expenses | JP¥617.00m |
| Earnings | -JP¥598.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -75.87 |
| Gross Margin | 47.50% |
| Net Profit Margin | -1,495.00% |
| Debt/Equity Ratio | 0% |
How did 4894 perform over the long term?
See historical performance and comparison